← Feed

$BLLN

2 theses
bullish 100%neutral 0%bearish 0%
Avg return (3m)
+74.8%
Win rate (3m)
100% (2 resolved)
1d3d1w1m3m6m1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Sep 8, 4:30 PM ET
$BLLNr/wallstreetbetsDDbullish
u/SkyFew229 · 125d ago1 prior · 100% at 3mo
Long BLLN $125C exp Dec 18 · 6 contracts

Why BillionToOne ($BLLN) will moonshot

Author holds 6 call option contracts with December 18, 2026 expiry at $125 strike, reflecting conviction in significant upside over the next 18+ months as oncology scales and coverage expands.

At post $81.40Now $99.06+21.7% since postedas of Sep 8, 4:30 PM ET
1d+14.1%
3d+14.2%
1w+11.3%
1m+19.4%
3m+74.8%
6m—
1y—
original post →
$BLLNr/wallstreetbetsDDbullish
u/SkyFew229 · 125d ago1 prior · 100% at 3mo
Long 1,420 shares of BLLN

Why BillionToOne ($BLLN) will moonshot

BillionToOne's QCT platform offers 1000x sensitivity over standard sequencing and is expanding beyond prenatal into oncology and other markets. With 100%+ revenue growth, GAAP profitability, strong FCF, and a founder-scientist CEO with a perfect execution track record, the company could grow to $3-5B+ in revenue long-term and reach $25-40B in market cap.

At post $81.40Now $99.06+21.7% since postedas of Sep 8, 4:30 PM ET
1d+14.1%
3d+14.2%
1w+11.3%
1m+19.4%
3m+74.8%
6m—
1y—
original post →

End of results.